LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

Начало・Списък с акции・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

22.91 -0.43

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

22.45

Максимум

23.23

Ключови измерители
By Trading Economics
Приходи	675K 53M
Продажби	1.8M 148M
P/E Средно за сектора	13.269 80.03
Марж на печалбата	35.57
Служители	181
EBITDA	1.7M 80M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+47.19% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	165M 2.8B
Предишно отваряне	23.34
Предишно затваряне	22.91

Настроения в новините

By Acuity

34%

66%

101 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

N/A / 24.28 Подкрепа & съпротива

Catalyst Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.12.2025 г., 23:21 ч. UTC

Печалби

Придобивния, сливания и поглъщания

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3.12.2025 г., 23:14 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3.12.2025 г., 22:01 ч. UTC

Значими двигатели на пазара

Costco Wholesale Reports Higher Monthly Sales

3.12.2025 г., 21:38 ч. UTC

Печалби

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3.12.2025 г., 23:59 ч. UTC

Пазарно говорене

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3.12.2025 г., 23:13 ч. UTC

Пазарно говорене

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3.12.2025 г., 23:10 ч. UTC

Печалби

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3.12.2025 г., 23:08 ч. UTC

Пазарно говорене

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3.12.2025 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3.12.2025 г., 22:59 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy PC Financial From Loblaw for About $573.5M

3.12.2025 г., 22:45 ч. UTC

Пазарно говорене

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3.12.2025 г., 22:20 ч. UTC

Печалби

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3.12.2025 г., 22:19 ч. UTC

Печалби

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3.12.2025 г., 22:17 ч. UTC

Печалби

Salesforce Working to Add Voice to Agentforce, CEO Says

3.12.2025 г., 22:16 ч. UTC

Печалби

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3.12.2025 г., 22:15 ч. UTC

Печалби

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3.12.2025 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3.12.2025 г., 22:09 ч. UTC

Придобивния, сливания и поглъщания

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

3.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

3.12.2025 г., 21:49 ч. UTC

Печалби

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:23 ч. UTC

Печалби

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3.12.2025 г., 21:19 ч. UTC

Печалби

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:06 ч. UTC

Печалби

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:04 ч. UTC

Печалби

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3.12.2025 г., 21:04 ч. UTC

Печалби

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3.12.2025 г., 21:03 ч. UTC

Печалби

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Сравнение с други в отрасъла

Ценова промяна

Catalyst Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

47.19% нагоре

12-месечна прогноза

Среден 34 USD 47.19%

Висок 35 USD

Нисък 33 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Catalyst Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Catalyst Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 24.28Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Настроение

By Acuity

101 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.